文章核心观点 - 公司ADMA Biologics遭遇潜在的证券欺诈指控,投资者可能会提起集体诉讼以追回损失 [1][2] - 公司股价在9月30日季度报告公布后下跌超过18%,因为公司的独立注册会计师CohnReznick不再担任该角色 [2] 公司信息 - ADMA Biologics是一家生物制药公司,主要从事血液制品的研发和生产 [1] - 公司股票在纳斯达克上市,股票代码为ADMA [1] 投资者权益 - 投资者可以免费联系律师事务所,了解如何追回投资损失 [1][2] - 律师事务所的创始合伙人已经帮助投资者追回超过55亿美元的损失 [2]

文章核心观点 - 公司ADMA Biologics的股票在2024年10月10日下跌近20%,原因是公司在盘后宣布其独立审计师CohnReznick辞职 [1][2] - 律所Block & Leviton正在调查公司是否存在证券法违规行为,并可能代表投资者提起诉讼以试图收回损失 [4] - 任何购买过ADMA Biologics普通股并遭受损失的投资者都可能有资格参与,无论是否已经出售投资 [3] - 如果投资者对公司有非公开信息,可以考虑协助调查或通过SEC的举报人计划提供信息,举报人最高可获得30%的赔付 [6] 公司信息 - ADMA Biologics是一家生物制药公司,其股票代码为Nasdaq: ADMA [1] - 公司的独立审计师CohnReznick已经辞职 [1][2] 律所信息 - Block & Leviton是一家广受好评的证券集体诉讼律所,其律师已经帮助投资者收回了数十亿美元的损失 [7] - 许多顶级机构投资者都聘请Block & Leviton代表他们的利益 [7] - 投资者可以通过电话、电子邮件或网站了解更多信息 [7]

The most recent trading session ended with Adma Biologics (ADMA) standing at $20.33, reflecting a -1.91% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.71%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 19.84% in the past month, leading the Medical sector's loss of 3.33% and the S&P 500's gain of 6.41%.The upcoming earnings release of Adma Biologic ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics (ADMA) : This specialty immune globulin company which develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 40% over the last 60 days.Vertex (VERX) : This company which provides tax technology solutions for corporations in retail, leasing, communication and manufactu ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

The latest trading session saw Adma Biologics (ADMA) ending at $19.44, denoting a -0.26% adjustment from its last day's close. This change lagged the S&P 500's 0.4% gain on the day. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 13.05% in the past month, leading the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%.Market participants will be closely following the financial results of Adma Biologics in ...

ADMA Biologics, Inc.’s (ADMA) shares skyrocketed 76.2% in the past three months compared with the industry’s growth of 9.6%. The stock also hit a new 52-week high of $19.34 on Sept. 9.The stupendous rally can be attributed to the company’s impressive performance year to date. Sales in the first half increased 61%. Last month, the company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA Outperf ...

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA’s inclusion in the S&P SmallCap 600 index is a sig ...

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term ...

Have you been paying attention to shares of Adma Biologics (ADMA) ? Shares have been on the move with the stock up 11.7% over the past month. The stock hit a new 52-week high of $19.34 in the previous session. Adma Biologics has gained 306.6% since the start of the year compared to the 10.3% move for the Zacks Medical sector and the 0% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't mi ...